ESG
Cardinal Health sets new benchmark in sustainability
In an era where sustainability has become a corporate buzzword, Jane Crowe, Managing Director of Cardinal Health ANZ, is pushing for real action.
In an exclusive podcast, she dissected the government’s climate commitments, the medtech industry’s sustainability roadblocks, and why Australia is at the heart of Cardinal Health’s next big move.
Last August, Assistant Health Minister Ged Kearney established an advisory group to address the health impacts of climate change, following the release of the National Health and Climate Strategy. But has it driven meaningful change, or is it yet another government talkfest?
Cardinal Health is making a game-changing move: its first remanufacturing facility outside the U.S. will be in Newcastle. But why Australia, and why now?
As a key member of the MTAA Sustainability Forum, Crowe is on the frontline of medtech’s sustainability challenges. The industry’s carbon footprint is massive, but slashing emissions isn’t as straightforward as it sounds. Supply chain complexities, regulatory hurdles, and reporting challenges all play a role in slowing progress.
With an election looming, Crowe didn’t hold back on what she wants from policymakers. She outlined a vision for a more climate-conscious future – one where sustainability isn’t an afterthought but a core business imperative.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

‘Trust ebbing away’: HTA reforms suffocate under bureaucracy while patients wait
It’s been over two years since the Health Technology Assessment (HTA) Review commenced and more than six months since the […]
MoreNews & Trends - Pharmaceuticals

First targeted therapy for rare lung cancer mutation PBS-listed
Australians diagnosed with an aggressive and hard-to-treat form of lung cancer, most common in people who have never smoked, now […]
MoreNews & Trends - Pharmaceuticals

Longer-acting schizophrenia therapy now PBS-listed
From 1 May 2025, Australian adults living with schizophrenia will have access to a long-acting injectable antipsychotic, Abilify Asimtufii (aripiprazole), […]
MoreNews & Trends - Pharmaceuticals

Teva secures PBS listing of motor neurone disease therapy
Teva has welcomed the inclusion of Radicava (edaravone) IV infusion on the Pharmaceutical Benefits Scheme (PBS) for amyotrophic lateral sclerosis […]
More